CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS Law) is soliciting Capricor Therapeutics (NASDAQ: CAPR) investors to seek lead plaintiff appointments in a securities fraud class action, with a deadline of September 28, 2026. The complaint alleges Capricor changed the statistical analysis plan for deramiocel clinical data without FDA agreement before resubmitting its Biologics License Application, creating significant risk the agency would not approve the BLA for lack of sufficient evidence of effectiveness. The class period runs from December 17, 2025 to July 26, 2026, and the class has not yet been certified.
Key figures
- Class period
- December 17, 2025 to July 26, 2026
- Legal claims
- Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5
- Class certified
- No
- Lead plaintiff deadline
- September 28, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.